SPRB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SPRB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Spruce Biosciences's Ending Cash Position for the quarter that ended in Sep. 2024 was $60.09 Mil.
Spruce Biosciences's quarterly Ending Cash Position declined from Mar. 2024 ($81.19 Mil) to Jun. 2024 ($69.72 Mil) and declined from Jun. 2024 ($69.72 Mil) to Sep. 2024 ($60.09 Mil).
Spruce Biosciences's annual Ending Cash Position declined from Dec. 2021 ($42.96 Mil) to Dec. 2022 ($24.73 Mil) but then increased from Dec. 2022 ($24.73 Mil) to Dec. 2023 ($96.37 Mil).
The historical data trend for Spruce Biosciences's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spruce Biosciences Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Ending Cash Position | Get a 7-Day Free Trial | 3.92 | 157.37 | 42.96 | 24.73 | 96.37 |
Spruce Biosciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Ending Cash Position | Get a 7-Day Free Trial | 98.84 | 96.37 | 81.19 | 69.72 | 60.09 |
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Spruce Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as
Ending Cash Position | = | Beginning Cash Position | + | Net Change in Cash |
= | 24.732 | + | 71.642 | |
= | 96.37 |
Spruce Biosciences's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as
Ending Cash Position | = | Beginning Cash Position | + | Net Change in Cash |
= | 69.718 | + | -9.628 | |
= | 60.09 |
Thank you for viewing the detailed overview of Spruce Biosciences's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Percival Barretto-ko | director | 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO CA 94080 |
Niall O'donnell | director | C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105 |
Charlton Ralph William Iii | officer: Chief Medical Officer | 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94104 |
Javier B. Szwarcberg | director, officer: Chief Executive Officer | 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94014 |
Kirk Ways | director | C/O 2001 JUNIPERO SERRA BOULEVARD, SUITE 540, DALY CITY CA 94014 |
Camilla V Simpson | director | 20 ELAINE AVE., MILL VALLEY CA 94941 |
Jonas Hansson | director | 18 AVENUE D'OUCHY, LAUSANNE V8 CH-1006 |
Bali Muralidhar | director | C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077 |
Healthcap Viii, L.p. | 10 percent owner | 18 AVENUE D'OUCHY, C/O HEALTHCAP VIII GP SA, CH 1006 LAUSANNE V8 1006 |
Rivervest Venture Fund Iii (ohio), L.p. | 10 percent owner | 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502 |
Moghrabi Dina Chaya | director | 22 GLEDHOW GARDENS, FLAT 2, LONDON X0 SW5 0AZ |
Omega Fund Vi Gp Manager, Ltd. | 10 percent owner | 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
Omega Fund Vi Gp, L.p. | 10 percent owner | 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
Richard King | director, officer: Chief Executive Officer | C/O KOS PHARMACEUTICALS INC, 1001 BRICKELL AVE 25TH FL, MIAMI FL 33131 |
From GuruFocus
By Business Wire • 04-22-2024
By GuruFocus Research • 02-09-2024
By Business Wire • 03-14-2024
By Business Wire • 08-12-2024
By GuruFocus Research • 02-09-2024
By Business Wire • 01-22-2024
By Business Wire • 05-01-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 03-13-2024
By Business Wire • 05-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.